C-GXDCMaxwell Biosciences
peptidomimetics, broad-spectrum anti-infectives, innate immunity
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-GXDC
C-GXDCC-GXDCpeptidomimetics, broad-spectrum anti-infectives, innate immunity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Maxwell Biosciences peptidomimetics, broad-spectrum anti-infectives, innate immunity
Maxwell Biosciences is a preclinical stage biotechnology company founded in 2016 and based in Austin, Texas. Its CLAROMER platform develops biostable, low molecular weight peptidomimetic compounds designed to mimic innate immune peptides and target viruses, bacteria, fungi, and biofilms. The company states that its lead drug candidate MXB-22,510 has shown broad preclinical activity and that human trials are planned for 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Maxwell Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic